Search results
Results from the WOW.Com Content Network
Pneumonia: Visual disturbance, liver toxicity. [7] Spiramycin: Rovamycine: Mouth infections: Fidaxomicin: Dificid: Treatment of Clostridioides (formerly Clostridium) difficile infection. [8] May be more narrow-spectrum than vancomycin, resulting in less bowel microbiota alteration. [9] Nausea (11%), vomiting, and abdominal pain. [10]
Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat pneumonia, otitis media, strep throat, and cellulitis. [1] It is a less preferred option for pneumonia, otitis media, and strep throat which may be used in those with a severe penicillin allergy. [1] It is taken by mouth. [1]
Antibiotic synergy is desirable in a clinic sense for several reasons. At the patient level, the boosted antimicrobial potency provided by synergy allows the body to more rapidly clear infections, resulting in shorter courses of antibiotic therapy. [3] Shorter courses of therapy in turn reduce the effects of dose-related toxicity, if applicable ...
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
In those treated in hospital, more than 90% improve with the initial antibiotics. [29] For people with ventilator-acquired pneumonia, the choice of antibiotic therapy will depend on the person's risk of being infected with a strain of bacteria that is multi-drug resistant. [34]
Cefazolin, also known as cefazoline and cephazolin, is a first-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [2] Specifically it is used to treat cellulitis, urinary tract infections, pneumonia, endocarditis, joint infection, and biliary tract infections. [2]
The Drug-Resistant Streptococcus pneumoniae Working Group recommends fluoroquinolones be used for the ambulatory treatment of community-acquired pneumonia only after other antibiotic classes have been tried and failed, or in cases with demonstrated drug-resistant Streptococcus pneumoniae. [63]
[13] [15] Pneumonia is also the leading cause of death in children less than five years of age in low income countries. [15] The most common cause of pneumonia is pneumococcal bacteria, Streptococcus pneumoniae accounts for 2/3 of bacteremic pneumonias. [16] Invasive pneumococcal pneumonia has a mortality rate of around 20%. [14]